Literature DB >> 9971832

A conserved tryptophan-rich motif in the membrane-proximal region of the human immunodeficiency virus type 1 gp41 ectodomain is important for Env-mediated fusion and virus infectivity.

K Salzwedel1, J T West, E Hunter.   

Abstract

Mutations were introduced into the ectodomain of the human immunodeficiency virus type 1 (HIV-1) transmembrane envelope glycoprotein, gp41, within a region immediately adjacent to the membrane-spanning domain. This region, which is predicted to form an alpha-helix, contains highly conserved hydrophobic residues and is unusually rich in tryptophan residues. In addition, this domain overlaps the epitope of a neutralizing monoclonal antibody, 2F5, as well as the sequence corresponding to a peptide, DP-178, shown to potently neutralize virus. Site-directed mutagenesis was used to create deletions, substitutions, and insertions centered around a stretch of 17 hydrophobic and uncharged amino acids (residues 666 to 682 of the HXB2 strain of HIV-1) in order to determine the role of this region in the maturation and function of the envelope glycoprotein. Deletion of the entire stretch of 17 amino acids abrogated the ability of the envelope glycoprotein to mediate both cell-cell fusion and virus entry without affecting the normal maturation, transport, or CD4-binding ability of the protein. This phenotype was also demonstrated by substituting alanine residues for three of the five tryptophan residues within this sequence. Smaller deletions, as well as multiple amino acid substitutions, were also found to inhibit but not block cell-cell fusion. These results demonstrate the crucial role of a tryptophan-rich motif in gp41 during a post-CD4-binding step of glycoprotein-mediated fusion. The basis for the invariant nature of the tryptophans, however, appears to be at the level of glycoprotein incorporation into virions. Even the substitution of phenylalanine for a single tryptophan residue was sufficient to reduce Env incorporation and drop the efficiency of virus entry approximately 10-fold, despite the fact that the same mutation had no significant effect on syncytium formation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9971832      PMCID: PMC104494          DOI: 10.1128/JVI.73.3.2469-2480.1999

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  59 in total

1.  Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene.

Authors:  J Kimpton; M Emerman
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

2.  Retained in vitro infectivity and cytopathogenicity of HIV-1 despite truncation of the C-terminal tail of the env gene product.

Authors:  T Wilk; T Pfeiffer; V Bosch
Journal:  Virology       Date:  1992-07       Impact factor: 3.616

3.  Mutational analysis of conserved N-linked glycosylation sites of human immunodeficiency virus type 1 gp41.

Authors:  W R Lee; X F Yu; W J Syu; M Essex; T H Lee
Journal:  J Virol       Date:  1992-03       Impact factor: 5.103

4.  Effects of deletions in the cytoplasmic domain on biological functions of human immunodeficiency virus type 1 envelope glycoproteins.

Authors:  D H Gabuzda; A Lever; E Terwilliger; J Sodroski
Journal:  J Virol       Date:  1992-06       Impact factor: 5.103

Review 5.  Cholesterol as a target for toxins.

Authors:  B de Kruijff
Journal:  Biosci Rep       Date:  1990-04       Impact factor: 3.840

6.  Mutations in the leucine zipper of the human immunodeficiency virus type 1 transmembrane glycoprotein affect fusion and infectivity.

Authors:  J W Dubay; S J Roberts; B Brody; E Hunter
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

7.  Role of the fusogenic peptide sequence in syncytium induction and infectivity of human immunodeficiency virus type 2.

Authors:  K R Steffy; G Kraus; D J Looney; F Wong-Staal
Journal:  J Virol       Date:  1992-07       Impact factor: 5.103

8.  Truncation of the human immunodeficiency virus type 1 transmembrane glycoprotein cytoplasmic domain blocks virus infectivity.

Authors:  J W Dubay; S J Roberts; B H Hahn; E Hunter
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

9.  A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition.

Authors:  C Wild; T Oas; C McDanal; D Bolognesi; T Matthews
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-01       Impact factor: 11.205

10.  Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding.

Authors:  Q J Sattentau; J P Moore
Journal:  J Exp Med       Date:  1991-08-01       Impact factor: 14.307

View more
  182 in total

1.  Role of the membrane-proximal domain in the initial stages of human immunodeficiency virus type 1 envelope glycoprotein-mediated membrane fusion.

Authors:  I Muñoz-Barroso; K Salzwedel; E Hunter; R Blumenthal
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

2.  Structure-function studies of the self-assembly domain of the human immunodeficiency virus type 1 transmembrane protein gp41.

Authors:  Y Weng; Z Yang; C D Weiss
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

3.  The long cytoplasmic tail of gp41 is required in a cell type-dependent manner for HIV-1 envelope glycoprotein incorporation into virions.

Authors:  T Murakami; E O Freed
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

4.  The membrane-proximal stem region of vesicular stomatitis virus G protein confers efficient virus assembly.

Authors:  C S Robison; M A Whitt
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

5.  Fine definition of the epitope on the gp41 glycoprotein of human immunodeficiency virus type 1 for the neutralizing monoclonal antibody 2F5.

Authors:  C E Parker; L J Deterding; C Hager-Braun; J M Binley; N Schülke; H Katinger; J P Moore; K B Tomer
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

6.  Membrane interface-interacting sequences within the ectodomain of the human immunodeficiency virus type 1 envelope glycoprotein: putative role during viral fusion.

Authors:  T Suárez; W R Gallaher; A Agirre; F M Goñi; J L Nieva
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

7.  Direct evidence that C-peptide inhibitors of human immunodeficiency virus type 1 entry bind to the gp41 N-helical domain in receptor-activated viral envelope.

Authors:  Nicole R Kilgore; Karl Salzwedel; Mary Reddick; Graham P Allaway; Carl T Wild
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

8.  Sequential roles of receptor binding and low pH in forming prehairpin and hairpin conformations of a retroviral envelope glycoprotein.

Authors:  Shutoku Matsuyama; Sue Ellen Delos; Judith M White
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

Review 9.  Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1.

Authors:  Peter D Kwong; John R Mascola; Gary J Nabel
Journal:  Cold Spring Harb Perspect Med       Date:  2011-09       Impact factor: 6.915

10.  Membrane-proximal external HIV-1 gp41 motif adapted for destabilizing the highly rigid viral envelope.

Authors:  Beatriz Apellániz; Andrey Ivankin; Shlomo Nir; David Gidalevitz; José L Nieva
Journal:  Biophys J       Date:  2011-11-15       Impact factor: 4.033

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.